305 related articles for article (PubMed ID: 9831269)
41. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
Gardner JD; Gallo-Torres H; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2003 Nov; 18(9):891-905. PubMed ID: 14616153
[TBL] [Abstract][Full Text] [Related]
42. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Schwizer W; Thumshirn M; Dent J; Guldenschuh I; Menne D; Cathomas G; Fried M
Lancet; 2001 Jun; 357(9270):1738-42. PubMed ID: 11403809
[TBL] [Abstract][Full Text] [Related]
43. Review of esomeprazole in the treatment of acid disorders.
Johnson DA
Expert Opin Pharmacother; 2003 Feb; 4(2):253-64. PubMed ID: 12562316
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
45. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
46. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
Gardner JD; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2003 Jul; 18(1):133-40. PubMed ID: 12848635
[TBL] [Abstract][Full Text] [Related]
47. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients.
Juul-Hansen P; Rydning A; Jacobsen CD; Hansen T
Scand J Gastroenterol; 2001 Aug; 36(8):806-10. PubMed ID: 11495074
[TBL] [Abstract][Full Text] [Related]
48. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
[TBL] [Abstract][Full Text] [Related]
49. Lansoprazole: in the management of gastroesophageal reflux disease in children.
Scott LJ
Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106
[TBL] [Abstract][Full Text] [Related]
50. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
51. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Zheng RN
World J Gastroenterol; 2009 Feb; 15(8):990-5. PubMed ID: 19248200
[TBL] [Abstract][Full Text] [Related]
52. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
Kovacs TO; Wilcox CM; DeVault K; Miska D; Bochenek W;
Aliment Pharmacol Ther; 2002 Dec; 16(12):2043-52. PubMed ID: 12452936
[TBL] [Abstract][Full Text] [Related]
53. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Richter JE; Kovacs TO; Greski-Rose PA; Huang section sign B; Fisher R
Aliment Pharmacol Ther; 1999 Jun; 13(6):795-804. PubMed ID: 10383510
[TBL] [Abstract][Full Text] [Related]
54. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
Bate CM; Green JR; Axon AT; Murray FE; Tildesley G; Emmas CE; Taylor MD
Aliment Pharmacol Ther; 1997 Aug; 11(4):755-63. PubMed ID: 9305486
[TBL] [Abstract][Full Text] [Related]
55. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Langtry HD; Wilde MI
Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
[TBL] [Abstract][Full Text] [Related]
56. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
[TBL] [Abstract][Full Text] [Related]
57. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Farup PG; Juul-Hansen PH; Rydning A
J Clin Gastroenterol; 2001 Sep; 33(3):206-9. PubMed ID: 11500608
[TBL] [Abstract][Full Text] [Related]
58. On-demand PPI requirements in patients with endoscopy-negative GERD.
Juul-Hansen P; Rydning A
J Clin Gastroenterol; 2004 Oct; 38(9):746-9. PubMed ID: 15365398
[TBL] [Abstract][Full Text] [Related]
59. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study.
Fass R; Murthy U; Hayden CW; Malagon IB; Pulliam G; Wendel C; Kovacs TO
Aliment Pharmacol Ther; 2000 Dec; 14(12):1595-603. PubMed ID: 11121907
[TBL] [Abstract][Full Text] [Related]
60. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.
Hatlebakk JG; Berstad A; Carling L; Svedberg LE; Unge P; Ekström P; Halvorsen L; Stallemo A; Hovdenak N; Trondstad R
Scand J Gastroenterol; 1993 Mar; 28(3):224-8. PubMed ID: 8446846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
